1
|
Han C, Guo C, Zheng X, Zhao L, Sun M, Li J, Wang S, Zhang Z, Wang Z, Wu L. Discovery of 2,4-dianilinopyrimidine derivatives as novel p90 ribosomal S6 protein kinase (RSK) inhibitors. Eur J Med Chem 2025; 291:117590. [PMID: 40199026 DOI: 10.1016/j.ejmech.2025.117590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2025] [Revised: 03/14/2025] [Accepted: 03/30/2025] [Indexed: 04/10/2025]
Abstract
RSK, or p90 ribosomal S6 kinase, plays a crucial role in tumor cell proliferation and survival, making it an appealing target for cancer therapies. With the aim to explore novel RSK inhibitors as anticancer agents, a series of 2,4-dianilinopyrimidine derivatives 2b-2n and 3a-3n have been designed and synthesized. Among them, compound 3e displayed substantial kinase inhibitory activity against RSK2 (IC50 = 37.89 ± 3.08 nM) and a potent antiproliferative effect against a range of cell lines, including HeLa, MIA PaCa-2, U937, SW620, HT-29, AGS, and two kinds of EGFR mutant cells (IC50s = 0.189-0.572 μM). Additionally, compound 3e exhibited a high affinity for RSK and effectively inhibited RSK activity in HeLa cells. It triggered significant apoptosis and caused cell cycle arrest in the G2/M phase. Moreover, 3e displayed considerable in vivo anticancer activity while maintaining an acceptable safety profile. These findings imply that compound 3e, featuring a 2,4-dianilinopyrimidine scaffold, could serve as a promising RSK inhibitor for cancer treatment.
Collapse
Affiliation(s)
- Chun Han
- Key Laboratory of Antitumor Drugs and Companion Diagnostic Reagents, Department of Chemistry, Changzhi University, Changzhi, 046011, China
| | - Chaohua Guo
- Key Laboratory of Antitumor Drugs and Companion Diagnostic Reagents, Department of Chemistry, Changzhi University, Changzhi, 046011, China; School of Chemistry & Material Science, Shanxi Normal University, Taiyuan, 030006, China
| | - Xumei Zheng
- Key Laboratory of Antitumor Drugs and Companion Diagnostic Reagents, Department of Chemistry, Changzhi University, Changzhi, 046011, China; School of Chemistry & Material Science, Shanxi Normal University, Taiyuan, 030006, China
| | - Lin Zhao
- Key Laboratory of Antitumor Drugs and Companion Diagnostic Reagents, Department of Chemistry, Changzhi University, Changzhi, 046011, China; School of Chemistry & Material Science, Shanxi Normal University, Taiyuan, 030006, China
| | - Miao Sun
- College of Pharmacy, Jinan University, Guangzhou, 510632, China
| | - Jian Li
- Key Laboratory of Antitumor Drugs and Companion Diagnostic Reagents, Department of Chemistry, Changzhi University, Changzhi, 046011, China
| | - Shijun Wang
- Key Laboratory of Antitumor Drugs and Companion Diagnostic Reagents, Department of Chemistry, Changzhi University, Changzhi, 046011, China
| | - Zhang Zhang
- College of Pharmacy, Jinan University, Guangzhou, 510632, China.
| | - Zhijun Wang
- Key Laboratory of Antitumor Drugs and Companion Diagnostic Reagents, Department of Chemistry, Changzhi University, Changzhi, 046011, China.
| | - Lintao Wu
- Key Laboratory of Antitumor Drugs and Companion Diagnostic Reagents, Department of Chemistry, Changzhi University, Changzhi, 046011, China.
| |
Collapse
|
2
|
Building 2D classification models and 3D CoMSIA models on small-molecule inhibitors of both wild-type and T790M/L858R double-mutant EGFR. Mol Divers 2021; 26:1715-1730. [PMID: 34636023 DOI: 10.1007/s11030-021-10300-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2021] [Accepted: 08/17/2021] [Indexed: 10/20/2022]
Abstract
Epidermal growth factor receptor (EGFR) has received widespread attention because it is an important target for anticancer drug design. Mutations in the EGFR, especially the T790M/L858R double mutation, have made cancer treatment more difficult. We herein built the structure-activity relationship models of small-molecule inhibitors on wild-type and T790M/L858R double-mutant EGFR with a whole dataset of 379 compounds. For 2D classification models, we used ECFP4 fingerprints to build support vector machine and random forest models and used SMILES to build self-attention recurrent neural network models. Each of all six models resulted in an accuracy of above 0.87 and the Matthews correlation coefficient value of above 0.76 on the test set, respectively. We concluded that inhibitors containing anilinoquinoline and methoxy or fluoro phenyl are highly active against wild EGFR. Substructures such as anilinopyrimidine, acrylamide, amino phenyl, methoxy phenyl, and thienopyrimidinyl amide appeared more in highly active inhibitors against double-mutant EGFR. We also used self-organizing map to cluster the inhibitors into six subsets based on ECFP4 fingerprints and analyzed the activity characteristics of different scaffolds in each subset. Among them, three datasets, which are based on pteridin, anilinopyrimidine, and anilinoquinoline scaffold, were selected to build 3D comparative molecular similarity analysis models individually. Models with the leave-one-out coefficient of determination (q2) above 0.65 were selected, and five descriptor types (steric, electrostatic, hydrophobic, donor, and acceptor) were used to study the effects of side chains of inhibitors on the activity against wild-type and mutant-type EGFR.
Collapse
|
3
|
Zhang Y, Yang J, Meng T, Qin Y, Li T, Fu J, Yin J. Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents. Eur J Med Chem 2021; 212:113153. [PMID: 33453603 DOI: 10.1016/j.ejmech.2021.113153] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2020] [Revised: 12/31/2020] [Accepted: 01/01/2021] [Indexed: 12/13/2022]
Abstract
Metal ion chelators based on 8-hydroxyquinoline (8-HQ) have been widely explored for the treatment of many diseases. When aimed at being developed into potent anticancer agent, a largely unmet issue is how to avoid nonspecific chelation of metal ions by 8-HQ in normal cells or tissues. In the current work, a two-step strategy was employed to both enhance the anticancer activity of 8-HQ and improve its cancer cell specificity. Considering the well-known anticancer activity of nitric oxide (NO), NO donor furoxan was first connected to 8-HQ to construct HQ-NO conjugates. These conjugates were screened for their cytotoxicity, metal-binding ability, and NO-releasing efficiency. Selected conjugates were further modified with a ROS-responsive moiety to afford prochelators. Among all the target compounds, prodrug HQ-NO-11 was found to potently inhibit the proliferation of many cancer cells but not normal cells. The abilities of metal chelation and NO generation by HQ-NO-11 were confirmed by various methods and were demonstrated to be essential for the anticancer activity of HQ-NO-11. In vivo studies revealed that HQ-NO-11 inhibited the growth of SW1990 xenograft to a larger extent than 8-HQ. Our results showcase a general method for designing novel 8-HQ derivatives and shed light on obtaining more controllable metal chelators.
Collapse
Affiliation(s)
- Yuxia Zhang
- School of Pharmacy, Nanjing Medical University, Nanjing, 211166, PR China
| | - Jiaxin Yang
- Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi, 214122, PR China
| | - Tingting Meng
- School of Pharmacy, Nanjing Medical University, Nanjing, 211166, PR China
| | - Yajuan Qin
- School of Pharmacy, Nanjing Medical University, Nanjing, 211166, PR China
| | - Tingyou Li
- School of Pharmacy, Nanjing Medical University, Nanjing, 211166, PR China.
| | - Junjie Fu
- Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi, 214122, PR China.
| | - Jian Yin
- Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi, 214122, PR China.
| |
Collapse
|
4
|
Yang H, Wang X, Wang C, Yin F, Qu L, Shi C, Zhao J, Li S, Ji L, Peng W, Luo H, Cheng M, Kong L. Optimization of WZ4003 as NUAK inhibitors against human colorectal cancer. Eur J Med Chem 2020; 210:113080. [PMID: 33310286 DOI: 10.1016/j.ejmech.2020.113080] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2020] [Revised: 11/16/2020] [Accepted: 12/01/2020] [Indexed: 10/22/2022]
Abstract
NUAK, the member of AMPK (AMP-activated protein kinase) family of protein kinases, is phosphorylated and activated by the LKB1 (liver kinase B1) tumor suppressor protein kinase. Recent work has indicated that NUAK1 is a key component of the antioxidant stress response pathway, and the inhibition of NUAK1 will suppress the growth and survival of colorectal tumors. As a promising target for anticancer drugs, few inhibitors of NUAK were developed. With this goal in mind, based on NUAK inhibitor WZ4003, a series of derivatives has been synthesized and evaluated for anticancer activity. Compound 9q, a derivative of WZ4003 by removing a methoxy group, was found to be the most potential one with stronger inhibitory against NUAK1/2 enzyme activity, tumor cell proliferation and inducing apoptosis of tumor cells. By in vivo efficacy evaluations of colorectal SW480 xenografts, 9q suppresses tumor growth more effectively with an excellent safety profile in vivo and is therefore seen as a suitable candidate for further investigation.
Collapse
Affiliation(s)
- Huali Yang
- Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing, 210009, China; School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, 110016, China
| | - Xiaobing Wang
- Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing, 210009, China
| | - Cheng Wang
- Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing, 210009, China
| | - Fucheng Yin
- Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing, 210009, China
| | - Lailiang Qu
- Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing, 210009, China
| | - Cunjian Shi
- Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing, 210009, China
| | - Jinhua Zhao
- Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing, 210009, China
| | - Shang Li
- Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing, 210009, China
| | - Limei Ji
- Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing, 210009, China
| | - Wan Peng
- Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing, 210009, China
| | - Heng Luo
- Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing, 210009, China
| | - Maosheng Cheng
- School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, 110016, China.
| | - Lingyi Kong
- Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing, 210009, China; School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, 110016, China.
| |
Collapse
|
5
|
Han C, Ren J, Su F, Hu X, Li M, Wang Z, Wu L. Hybrids of Quinoline and Anilinopyrimidine: Novel EGFRT790M Inhibitors with Antiproliferative Activity against Non-Small Cell Lung Cancer Cell Lines. Anticancer Agents Med Chem 2020; 20:724-733. [PMID: 32116203 DOI: 10.2174/1871520620666200302113206] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2019] [Revised: 10/24/2019] [Accepted: 01/27/2020] [Indexed: 12/30/2022]
Abstract
BACKGROUND The third-generation irreversible Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) inhibit the T790M mutation while sparing EGFRWT. However, the C797S point mutation confers resistance to existing irreversible EGFRT790M inhibitors. OBJECTIVE Novel EGFRT790M inhibitors were designed through hybridization of quinoline and anilinopyrimidine, and biologically evaluated their antiproliferative activity against Non-Small Cell Lung Cancer (NSCLC) cell lines. METHODS The target compounds 11a-h were synthesized and structurally characterized with 1H, 13C Nuclear Magnetic Resonance (NMR) spectroscopy and High-Resolution Mass Spectrometry (HRMS). Their inhibitory effects on tumor cell proliferation and EGFR kinase were biologically evaluated. Additionally, molecular docking studies were also performed on the representative typical EGFRT790M inhibitor. RESULTS Most of the evaluated compounds displayed moderate antiproliferative activity on H1975 cells with EGFRL858R/T790M. However, compound 11a (IC50 = 2.235 ± 0.565μM) showed stronger inhibition than gefitinib (IC50 = 8.830 ± 0.495μM) in concentration- and time-dependent manner. Moreover, compound 11a exhibited weaker inhibitory activities on cells with EGFRWT. Specifically, compound 11a strongly suppressed EGFRL858R/T790M (IC50 = 0.515 ± 0.011μM) relative to EGFRWT (IC50 = 0.913 ± 0.068μM). Furthermore, molecular docking studies demonstrated its strong binding contacts with the EGFRT790M enzyme through hydrogen bonds and other non-bonded interactions. CONCLUSION Taken together, these results indicate that the hybrid of quinoline and anilinopyrimidine 11a, could be a potential inhibitor of EGFRT790M in NSCLC, which warrants further in-depth studies.
Collapse
Affiliation(s)
- Chun Han
- Department of Chemistry, Changzhi University, Shanxi, Changzhi 046011, China
| | - Jiahong Ren
- Department of Biology, Changzhi University, Shanxi, Changzhi 046011, China
| | - Feng Su
- Department of Chemistry, Changzhi University, Shanxi, Changzhi 046011, China
| | - Xiaoqin Hu
- Department of Chemistry, Changzhi University, Shanxi, Changzhi 046011, China
| | - Mengyao Li
- Department of Chemistry, Changzhi University, Shanxi, Changzhi 046011, China
| | - Zhijun Wang
- Department of Chemistry, Changzhi University, Shanxi, Changzhi 046011, China
| | - Lintao Wu
- Department of Chemistry, Changzhi University, Shanxi, Changzhi 046011, China
| |
Collapse
|
6
|
Stolpovskaya NV, Kruzhilin AA, Zorina AV, Shikhaliev KS, Ledeneva IV, Kosheleva EA, Vandyshev DY. Synthesis of Substituted Aminopyrimidines as Novel Promising Tyrosine Kinase Inhibitors. RUSSIAN JOURNAL OF ORGANIC CHEMISTRY 2019. [DOI: 10.1134/s1070428019090094] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
7
|
Zhang D, Yan Y, Jin G, Liu B, Ma X, Han D, Jia X. Synthesis and antitumor evaluation of novel 4-anilino-7,8-dihydropyrido[4,3-d
]pyrimidine-6(5H
)-carboxylate derivatives as potential EGFR inhibitors. Arch Pharm (Weinheim) 2018; 351:e1800110. [DOI: 10.1002/ardp.201800110] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2018] [Revised: 06/27/2018] [Accepted: 06/29/2018] [Indexed: 11/06/2022]
Affiliation(s)
- Dajun Zhang
- Key Laboratory of Behavioral and Cognitive Neuroscience of Liaoning Province; Shenyang Medical College; Shenyang China
| | - Yan Yan
- School of Information Engineering; Liaoning University of Traditional Chinese Medicine; Shenyang China
| | - Ge Jin
- Key Laboratory of Behavioral and Cognitive Neuroscience of Liaoning Province; Shenyang Medical College; Shenyang China
| | - Bo Liu
- Key Laboratory of Behavioral and Cognitive Neuroscience of Liaoning Province; Shenyang Medical College; Shenyang China
| | - Xiaoliang Ma
- Key Laboratory of Behavioral and Cognitive Neuroscience of Liaoning Province; Shenyang Medical College; Shenyang China
| | - Dan Han
- Key Laboratory of Behavioral and Cognitive Neuroscience of Liaoning Province; Shenyang Medical College; Shenyang China
| | - Xiaojian Jia
- Department of Child Psychiatry, Shenzhen Kangning Hospital and Shenzhen Mental Health Center; Shenzhen University Health Science Center; Shenzhen China
| |
Collapse
|
8
|
Sheng J, Liu Z, Yan M, Zhang X, Wang D, Xu J, Zhang E, Zou Y. Biomass-involved synthesis of N-substituted benzofuro[2,3-d]pyrimidine-4-amines and biological evaluation as novel EGFR tyrosine kinase inhibitors. Org Biomol Chem 2018; 15:4971-4977. [PMID: 28548166 DOI: 10.1039/c7ob00793k] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Shikimic acid (1) is a renewable biomass which could be obtained sustainably through natural product isolation or metabolic engineering. Owing to its great potential in chemical conversion, the value-added utilization of this non-grain biomass has received much attention in recent years. Based on the established transformation route from shikimic acid (1) to methyl 3-dehydroshikimate (3-MDHS, 2) and to the multi-functionalized methyl 2-amino-3-cyanobenzofuran-5-carboxylate (3), we disclose a facile and transition metal-free method to access a series of N-substituted benzofuro[2,3-d]pyrimidine-4-amines in 63%-90% yields. The identification of these compounds as EGFR tyrosine kinase inhibitors has also been described. Among them, compound 5h exhibited the most potent inhibitory effect against EGFR tyrosine kinase with an IC50 of 1.7 nM and excellent antiproliferative activity against A431 and A549 cell lines with a GI50 of 5.1 and 12.3 μM, respectively.
Collapse
Affiliation(s)
- Jianfei Sheng
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, People's Republic of China.
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Hu X, Wang D, Tong Y, Tong L, Wang X, Zhu L, Xie H, Li S, Yang Y, Xu Y. Design, Synthesis, and Evaluation of Ribose-Modified Anilinopyrimidine Derivatives as EGFR Tyrosine Kinase Inhibitors. Front Chem 2017; 5:101. [PMID: 29250520 PMCID: PMC5715404 DOI: 10.3389/fchem.2017.00101] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2017] [Accepted: 10/30/2017] [Indexed: 12/21/2022] Open
Abstract
The synthesis of a series of ribose-modified anilinopyrimidine derivatives was efficiently achieved by utilizing DBU or tBuOLi-promoted coupling of ribosyl alcohols with 2,4,5-trichloropyrimidine as key step. Preliminary biological evaluation of this type of compounds as new EGFR tyrosine kinase inhibitors for combating EGFR L858R/T790M mutant associated with drug resistance in the treatment of non-small cell lung cancer revealed that 3-N-acryloyl-5-O-anilinopyrimidine ribose derivative 1a possessed potent and specific inhibitory activity against EGFR L858R/T790M over WT EGFR. Based upon molecular docking studies of the binding mode between compound 1a and EGFR, the distance between the Michael receptor and the pyrimidine scaffold is considered as an important factor for the inhibitory potency and future design of selective EGFR tyrosine kinase inhibitors against EGFR L858R/T790M mutants.
Collapse
Affiliation(s)
- Xiuqin Hu
- Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China
| | - Disha Wang
- Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China
| | - Yi Tong
- Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China
| | - Linjiang Tong
- Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
| | - Xia Wang
- Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China
| | - Lili Zhu
- Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China
| | - Hua Xie
- Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
| | - Shiliang Li
- Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China
| | - You Yang
- Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China
| | - Yufang Xu
- Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China
| |
Collapse
|
10
|
Shi W, Zhang J, Bao N, Guan F, Chen L, Sun J. Design, synthesis, and cytotoxic evaluation of novel scopoletin derivatives. Chem Biol Drug Des 2017; 91:641-646. [DOI: 10.1111/cbdd.13120] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2017] [Revised: 07/08/2017] [Accepted: 10/04/2017] [Indexed: 12/27/2022]
Affiliation(s)
- Wei Shi
- Department of Natural Medicinal Chemistry; China Pharmaceutical University; Nanjing China
| | - Jinlu Zhang
- Department of Natural Medicinal Chemistry; China Pharmaceutical University; Nanjing China
| | - Na Bao
- Department of Natural Medicinal Chemistry; China Pharmaceutical University; Nanjing China
| | - Fuqin Guan
- Institute of Botany; Jiangsu Province and Chinese Academy of Science; Nanjing China
| | - Li Chen
- Department of Natural Medicinal Chemistry; China Pharmaceutical University; Nanjing China
| | - Jianbo Sun
- Department of Natural Medicinal Chemistry; China Pharmaceutical University; Nanjing China
| |
Collapse
|
11
|
Joshi G, Nayyar H, Kalra S, Sharma P, Munshi A, Singh S, Kumar R. Pyrimidine containing epidermal growth factor receptor kinase inhibitors: Synthesis and biological evaluation. Chem Biol Drug Des 2017; 90:995-1006. [PMID: 28544624 DOI: 10.1111/cbdd.13027] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2017] [Revised: 05/02/2017] [Accepted: 05/03/2017] [Indexed: 12/15/2022]
Abstract
Structure-based design and synthesis of pyrimidine containing reversible epidermal growth factor receptor (EGFR) inhibitors 1a-d are reported. The compounds (1a-d) inhibited the EGFR kinase activity in vitro with IC50 range 740 nm to 3 μm. mRNA expression of EGFR downstream target genes, that is twist, c-fos and aurora were found to be altered upon treatment with compounds 1a-d. The compounds 1a-d exhibited excellent anticancer activity at low micromolar level (3.2-9 μm) in lung, colon and breast cancer cell lines. Furthermore, compounds induced the alteration in mitochondrial membrane potential and reactive oxygen species level and. Selected compound 1b was found to increase sub-G1 population indicative of cell death, the mode of cell death was apoptotic as evident from Annexin V verses propidium iodide assay. Molecular modelling further helped to investigate the binding recognition pattern of the compounds in ATP binding EGFR domain similar to erlotinib and dissimilar to WZ4002.
Collapse
Affiliation(s)
- Gaurav Joshi
- Laboratory for Drug Design and Synthesis, Centre for Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, India
| | - Himanshu Nayyar
- Laboratory for Drug Design and Synthesis, Centre for Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, India
| | - Sourav Kalra
- Centre for Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda, India
| | - Praveen Sharma
- Centre for Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda, India
| | - Anjana Munshi
- Centre for Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda, India
| | - Sandeep Singh
- Centre for Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda, India
| | - Raj Kumar
- Laboratory for Drug Design and Synthesis, Centre for Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, India
| |
Collapse
|
12
|
Synthesis of 13-β-elemene ester derivatives and evaluation of their antioxidant activity in human umbilical vein endothelial cells. Chin J Nat Med 2016; 13:618-27. [PMID: 26253495 DOI: 10.1016/s1875-5364(15)30058-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2014] [Indexed: 11/21/2022]
Abstract
In the present study, a series of 13-β-elemene ester derivatives were designed and prepared, and their antioxidant activity was investigated in the H2O2-treated human umbilical vein endothelial cells (HUVECs). Among the test compounds, the dimer compounds 5v and 5w exhibited the most potent antioxidant activity with significant ROS suppression being observed. Both compounds markedly inhibited the H2O2-induced changes in various biochemical substances, such as superoxide dismutase (SOD), malonyldialdehyde (MDA), nitric oxide (NO), and lactic dehydrogenase (LDH), which were superior to that of the positive control vitamin E. Further more, they did not produce any obvious cytotoxicity, but increased the viability of HUVECs injured by H2O2 in a dose-dependent manner. Additionally, compound 5w, designed as a prodrug-like compound, showed improved stability relative to compound 4 in vitro.
Collapse
|
13
|
Koroleva EV, Ignatovich ZI, Sinyutich YV, Gusak KN. Aminopyrimidine derivatives as protein kinases inhibitors. Molecular design, synthesis, and biologic activity. RUSSIAN JOURNAL OF ORGANIC CHEMISTRY 2016. [DOI: 10.1134/s1070428016020019] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
14
|
Song Z, Ge Y, Wang C, Huang S, Shu X, Liu K, Zhou Y, Ma X. Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer. J Med Chem 2016; 59:6580-94. [PMID: 26882288 DOI: 10.1021/acs.jmedchem.5b00840] [Citation(s) in RCA: 72] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Because of the development of drug-resistance mutations, particularly the "gatekeeper" threonine(790)-to-methionine(790) (T790M) mutation in the ATP-binding pocket of the epidermal growth factor receptor (EGFR), the current generation of EGFR tyrosine kinase inhibitors lost their clinical efficacy. Recently, a large number of small-molecule inhibitors with striking inhibitory potency against EGFR mutants with the T790M change have been identified. In particular, the inhibitors rociletinib and osimertinib, which can selectively target both sensitizing mutations and the T790M resistance while sparing the wild-type (WT) form of the receptor, have been designated as breakthrough therapies in the treatment of mutant non-small-cell lung cancer (NSCLC) by the U.S. FDA in 2014. We hope that this review on the small-molecule EGFR T790M inhibitors, along with their discovery strategies, will assist in the design of future T790M-containing EGFR inhibitors with high levels of selectivity over WT EGFR, broad kinase selectivity, and desirable physicochemical properties.
Collapse
Affiliation(s)
- Zhendong Song
- College of Pharmacy, Dalian Medical University , Dalian 116044, P. R. China
| | - Yang Ge
- College of Pharmacy, Dalian Medical University , Dalian 116044, P. R. China
| | - Changyuan Wang
- College of Pharmacy, Dalian Medical University , Dalian 116044, P. R. China
| | - Shanshan Huang
- College of Pharmacy, Dalian Medical University , Dalian 116044, P. R. China
| | - Xiaohong Shu
- College of Pharmacy, Dalian Medical University , Dalian 116044, P. R. China
| | - Kexin Liu
- College of Pharmacy, Dalian Medical University , Dalian 116044, P. R. China
| | - Youwen Zhou
- Department of Dermatology and Skin Science, University of British Columbia , Vancouver, BC, V5Z 4E8, Canada
| | - Xiaodong Ma
- College of Pharmacy, Dalian Medical University , Dalian 116044, P. R. China
| |
Collapse
|
15
|
Zhang Y, Zhang K, Zhao M, Zhang L, Qin M, Guo S, Zhao Y, Gong P. Discovery of a novel class anti-proliferative agents and potential inhibitors of EGFR tyrosine kinases based on 4-anilinotetrahydropyrido[4,3-d]pyrimidine scaffold: Design, synthesis and biological evaluations. Bioorg Med Chem 2015; 23:4591-4607. [DOI: 10.1016/j.bmc.2015.05.059] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2015] [Revised: 05/29/2015] [Accepted: 05/30/2015] [Indexed: 10/23/2022]
|
16
|
Gd-Complexes of New Arylpiperazinyl Conjugates of DTPA-Bis(amides): Synthesis, Characterization and Magnetic Relaxation Properties. Molecules 2015; 20:7807-19. [PMID: 25939069 PMCID: PMC6272509 DOI: 10.3390/molecules20057807] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2015] [Revised: 04/22/2015] [Accepted: 04/24/2015] [Indexed: 11/16/2022] Open
Abstract
Two new DTPA-bis(amide) based ligands conjugated with the arylpiperazinyl moiety were synthesized and subsequently transformed into their corresponding Gd(III) complexes 1 and 2 of the type [Gd(L)H2O] nH2O. The relaxivity (R1) of these complexes was measured, which turned out to be comparable with that of Omniscan®, a commercially available MRI contrast agent. The cytotoxicity studies of these complexes indicated that they are non-toxic, which reveals their potential and physiological suitability as MRI contrast agents. All the synthesized ligands and complexes were characterized with the aid of analytical and spectroscopic methods, including elemental analysis, 1H-NMR, FT-IR, XPS and fast atom bombardment (FAB) mass spectrometry.
Collapse
|